Diabetes Innovation Award Program
Deadline for applications is August 1, 2012
Novo Nordisk is a world leader in diabetes treatment innovation and as such is committed to supporting novel research in protein-based therapies and technologies that have the potential to improve the effective treatment, prevention and/or cure of diabetes.
In keeping with this commitment, Novo Nordisk R&D has renewed its research award program to support new and established scientists in their exploration of novel hypotheses in the area of diabetes and obesity research. The aim of this research award program is to help scientists substantiate early innovation research efforts and clarify if their hypotheses could result in new treatment options for diabetes and obesity.
Only non-clinical research proposals from scientist at US and Canadian academic and medical research institutions are eligible for support.
The award program also targets novel research ideas that despite having potentially high impact would not normally attract funding from such institutions as the National Institutes of Health (NIH) or the Canadian Institutes of Health Research (CIHR).
Under the program, Novo Nordisk R&D offers two types of research funding opportunities: "Early Research Exploration" or "Proof of Principle" awards. The awards are reserved for nonclinical research only and projects can be supported for up to two years under the program.
Deadline
Electronic applications must be submitted by 8:00 PM Eastern Time on August 1st 2012. Applications received after the deadline will be administratively disapproved.
E-mail the application
Applications must be e-mailed to the program office at diabetesinnovation@novonordisk.com stating the type of award being applied for in the subject line.
Before submission
The Applicant must ensure that the proposed research will comply with host institution and Novo Nordisk research policies for conducting nonclinical research. Read more at Research Policies and Terms and Conditions.
Applicants must have the host institution’s approval prior to submission, including a statement of commitment that adequate lab space and facilities will be made available for the conduct of the research proposal.
Application guidelines
The application must not contain any confidential information. The Applicant is responsible for ensuring that all confidential information is removed prior to submission. Novo Nordisk will not be responsible for the confidentiality of any information submitted.The award program office will reject applications if there are markings of confidentiality.
The application must contain enough detail about the research proposal and funding request to enable Novo Nordisk to make a final evaluation regarding support.
The proposed research plan must contain appropriate milestones ensuring that progress can be monitored.
The application must comply with the proposed Table of Contents (ToC)
Applicants must submit an itemized budget form. Download Award Budget Form here
Applicants must convert the necessary components of their application into a single PDF document using the full version of Adobe Acrobat. Multiple attachments and other formats will not be accepted.
If the application contains pictures or scanned documents, the Applicant is requested to minimize the size of the application to no more than 10 MB.
After submission
The program office will acknowledge receipt of all award applications within one week following submission. Applicants will also be notified within one week if their application is disqualified due to confidential material, submission past deadline or noncompliance with award program terms.
Each Application will be reviewed by the Novo Nordisk R&D Award Review Committee. The Committee is comprised of senior scientists and management of Novo Nordisk R&D.
The review process will take approximately 8 weeks to complete (depending on the number of applications submitted) after which the program office will issue a formal notification on the status of each application.
Contact
Please direct any inquiries about these awards to the program office:
Kristian T Hansen, Director of the Diabetes Innovation Award Program
diabetesinnovation@novonordisk.com
